SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* AFEYAN NOUBAR (Last) (First) (Middle) C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR (Street) CAMBRIDGE MA 02142 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol BG Medicine, Inc. [ BGMD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 08/20/2012
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2012		X		2,353	A	$0.03	278,953	I	By NewcoGen-Elan LLC(1)
Common Stock	08/20/2012		S(2)		13	D	$5.83(3)	278,940	I	By NewcoGen-Elan LLC(1)
Common Stock	08/20/2012		X		6,422	A	$0.02	285,362	I	By NewcoGen-Elan LLC(1)
Common Stock	08/20/2012		S(4)		23	D	$5.83(3)	285,339	I	By NewcoGen-Elan LLC(1)
Common Stock	08/20/2012		X		6,422	A	$0.02	291,761	I	By NewcoGen-Elan LLC(1)
Common Stock	08/20/2012		S(5)		23	D	$5.83(3)	291,738	I	By NewcoGen-Elan LLC(1)
Common Stock	08/20/2012		X		6,422	A	$0.02	298,160	I	By NewcoGen-Elan LLC(1)
Common Stock	08/20/2012		S(6)		23	D	$5.83(3)	298,137	I	By NewcoGen-Elan LLC(1)
Common Stock	08/21/2012		J(7)		298,137	D	$0	0	I	By NewcoGen-Elan LLC(1)
Common Stock								526,560	I	By NewcoGen Equity Investors LLC(1)
Common Stock								92,294	I	By NewcoGen-Long Reign Holding LLC(1)
Common Stock								92,126	I	By ST NewcoGen LLC(1)
Common Stock								140,013	I	By AGTC Advisors Fund, L.P.(1)
Common Stock								2,351,447	I	By Applied Genomic Technology Capital Fund, L.P.(1)
Common Stock								2,184,800	I	By NewcoGen Group LLC(1)
Common Stock								4,232	I	By OneLiberty Advisors Fund 2000 L.P.(8)
Common Stock								80,424	I	By OneLiberty Ventures 2000 L.P.(8)
Common Stock								714,286	I	By Flagship Ventures Fund 2007, L.P.(9)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant to Purchase Common Stock (right to buy)	$0.03	08/20/2012		X			2,353	(10)	07/10/2016	Common Stock	2,353	$0	0	I	By NewcoGen-Elan LLC(1)
Warrant to Purchase Common Stock (right to buy)	$0.02	08/20/2012		X			6,422	(10)	03/30/2020	Common Stock	6,422	$0	0	I	By NewcoGen-Elan LLC(1)
Warrant to Purchase Common Stock (right to buy)	$0.02	08/20/2012		X			6,422	(10)	09/27/2020	Common Stock	6,422	$0	0	I	By NewcoGen-Elan LLC(1)
Warrant to Purchase Common Stock (right to buy)	$0.02	08/20/2012		X			6,422	(10)	11/04/2020	Common Stock	6,422	$0	0	I	By NewcoGen-Elan LLC(1)

1. Name and Address of Reporting Person* AFEYAN NOUBAR (Last) (First) (Middle) C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR (Street) CAMBRIDGE MA 02142 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer X Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* NewcoGen Elan LLC (Last) (First) (Middle) C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR (Street) CAMBRIDGE MA 02142 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* KANIA EDWIN M JR (Last) (First) (Middle) C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR (Street) CAMBRIDGE MA 02142 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Flagship Ventures Management, Inc. (Last) (First) (Middle) C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR (Street) CAMBRIDGE MA 02142 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* NewcoGen Group, Inc. (Last) (First) (Middle) C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR (Street) CAMBRIDGE MA 02142 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

Explanation of Responses:

1. NewcoGen Group, Inc. ("NG") is the manager of each of NewcoGen Group LLC ("NGG"), NewcoGen Equity Investors LLC ("NEI"), NewcoGen-Elan LLC ("NGE"), NewcoGen-Long Reign Holding LLC ("NGLRH") and ST NewcoGen LLC ("STN", and together with NGG, NEI, NGE and NGLRH, the "NewcoGen Funds"). NG is also the general partner of AGTC Partners, L.P., which is the general partner of AGTC Advisors Fund, L.P. ("AGTCA") and Applied Genomic Technology Capital Fund L.P. ("AGTCF", and together with AGTCA, the "AGTC Funds"). NG is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship"). Noubar Afeyan and Edwin M. Kania, Jr. are directors of Flagship and may be deemed to beneficially own the securities held by the NewcoGen Funds and the AGTC Funds. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.

2. On August 20, 2012, NGE exercised a warrant to purchase 2,353 shares of Common Stock for $0.03 per share. NGE exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 13 of the warrant shares to pay the exercise price and issuing to NGE the remaining 2,340 shares.

3. The price reflects the average of the closing prices of the Common Stock over the five day period prior to the exercise date.

4. On August 20, 2012, NGE exercised a warrant to purchase 6,422 shares of Common Stock for $0.02 per share. NGE exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 23 of the warrant shares to pay the exercise price and issuing to NGE the remaining 6,399 shares.

5. On August 20, 2012, NGE exercised a warrant to purchase 6,422 shares of Common Stock for $0.02 per share. NGE exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 23 of the warrant shares to pay the exercise price and issuing to NGE the remaining 6,399 shares.

6. On August 20, 2012, NGE exercised a warrant to purchase 6,422 shares of Common Stock for $0.02 per share. NGE exercised the warrant on a cashless basis, resulting in the Issuer's withholding of 23 of the warrant shares to pay the exercise price and issuing to NGE the remaining 6,399 shares.

7. In addition to the cashless exercises of the warrants reported above, this Form 4 is being filed to report an in-kind distribution for no consideration by NGE to its sole member. The beneficial ownership of the entities named in this Form 4, other than the Reporting Persons filing this Form 4, did not change as a result of this transaction.

8. Noubar Afeyan and Edwin M. Kania, Jr. are managing members of OneLiberty Partners 2000, LLC, which is the general partner of OneLiberty Advisors Fund 2000 L.P. ("OLA") and OneLiberty Ventures 2000 L.P. ("OLV"), and may be deemed to beneficially own the securities held by OLA and OLV. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.

9. Noubar Afeyan and Edwin M. Kania, Jr. are managers of Flagship Ventures 2007 General Partner, LLC, which is the general partner of Flagship Ventures Fund 2007, L.P., and may be deemed to beneficially own the securities held by Flagship Ventures Fund 2007, L.P. Each of Messrs. Afeyan and Kania disclaim beneficial ownership of the securities except to the extent of his pecuniary interest therein.

10. This warrant is immediately exercisable.

	/s/ John P. Condon, Attorney-in-fact for Noubar Afeyan	08/22/2012
	/s/ John P. Condon, Attorney-in-fact for NewcoGen-Elan LLC	08/22/2012
	/s/ John P. Condon, Attorney-in-fact for Edwin M. Kania, Jr.	08/22/2012
	/s/ John P. Condon, Attorney-in-fact for Flagship Ventures Management, Inc.	08/22/2012
	/s/ John P. Condon, Attorney-in-fact for NewcoGen Group, Inc.	08/22/2012
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.